Free Trial

Context Therapeutics (CNTX) Stock Price, News & Analysis

-0.05 (-2.44%)
(As of 06/12/2024 ET)
Today's Range
50-Day Range
52-Week Range
233,145 shs
Average Volume
346,569 shs
Market Capitalization
$150 million
P/E Ratio
Dividend Yield
Price Target

Context Therapeutics MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
200.0% Upside
$6.00 Price Target
Short Interest
2.01% of Float Sold Short
Dividend Strength
News Sentiment
1.87mentions of Context Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($0.75) to ($0.33) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.48 out of 5 stars

Medical Sector

468th out of 913 stocks

Pharmaceutical Preparations Industry

221st out of 429 stocks

CNTX stock logo

About Context Therapeutics Stock (NASDAQ:CNTX)

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

CNTX Stock Price History

CNTX Stock News Headlines

Context Therapeutics, Inc.
Context Therapeutics Submits IND For CTIM-76
See More Headlines
Receive CNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$0.74 per share


Free Float
Market Cap
$150 million
Not Optionable
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

CNTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Context Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Context Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CNTX shares.
View CNTX analyst ratings
or view top-rated stocks.

What is Context Therapeutics' stock price target for 2024?

4 brokers have issued 1 year target prices for Context Therapeutics' stock. Their CNTX share price targets range from $4.50 to $10.00. On average, they expect the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 200.0% from the stock's current price.
View analysts price targets for CNTX
or view top-rated stocks among Wall Street analysts.

How have CNTX shares performed in 2024?

Context Therapeutics' stock was trading at $1.13 at the beginning of 2024. Since then, CNTX shares have increased by 77.0% and is now trading at $2.00.
View the best growth stocks for 2024 here

Are investors shorting Context Therapeutics?

Context Therapeutics saw a increase in short interest during the month of May. As of May 31st, there was short interest totaling 1,320,000 shares, an increase of 30.7% from the May 15th total of 1,010,000 shares. Based on an average daily volume of 567,900 shares, the days-to-cover ratio is presently 2.3 days. Currently, 2.0% of the shares of the stock are short sold.
View Context Therapeutics' Short Interest

When is Context Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our CNTX earnings forecast

How were Context Therapeutics' earnings last quarter?

Context Therapeutics Inc. (NASDAQ:CNTX) announced its earnings results on Wednesday, May, 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.38) by $0.15.

When did Context Therapeutics IPO?

Context Therapeutics (CNTX) raised $25 million in an initial public offering (IPO) on Wednesday, October 20th 2021. The company issued 5,000,000 shares at a price of $5.00 per share.

Who are Context Therapeutics' major shareholders?

Context Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Opaleye Management Inc. (1.48%). Insiders that own company stock include Alex C Levit, Jennifer Lynn Minai-Azary and Martin A Lehr.
View institutional ownership trends

How do I buy shares of Context Therapeutics?

Shares of CNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CNTX) was last updated on 6/12/2024 by Staff

From Our Partners